CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 90 enrolled
Drug / intervention
LY2510924 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01439568
NCT01439568Phase 2Completed
CompareCT.gov

A Randomized Phase 2 Study of LY2510924 and Carboplatin/Etoposide Versus Carboplatin/Etoposide in Extensive-Stage Small Cell Lung Carcinoma

Eli Lilly and Company·interventional·Posted Sep 23, 2011·Updated Jul 23, 2019

In Brief

A Phase 2 clinical trial evaluating LY2510924, Carboplatin, and 1 other intervention for Extensive Stage Small Cell Lung Carcinoma. Completed, enrolled 90 participants across 15 sites.

Detailed Summary

The purpose of this trial is to compare the progression free survival of LY2510924 + carboplatin + etoposide therapy versus carboplatin + etoposide therapy in participants with extensive-stage disease small cell lung cancer (SCLC)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsExtensive Stage Small Cell Lung Carcinoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 23, 2011
Enrollment StartSep 1, 2011
Primary CompletionJan 1, 2014
Study CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 14.8 years ago

Interventions

LY2510924drug

Administered subcutaneous injection

Carboplatindrug

Administered intravenously

Etoposidedrug

Administered intravenously